Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
AbbVie, CervoMed, Thermo Fisher Scientific, Danaher, Vertex Pharmaceuticals, Cencora, and Cognizant Technology Solutions are the seven Biotech stocks to watch today, according to MarketBeat’s stock ...
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...
MoneyWeek on MSN7d
Vertex Pharmaceuticals is an uncommon opportunity in rare diseasesVertex Pharmaceuticals operates in a profitable subsector and is poised for further success, says Dr Michael Tubbs ...
That's encouraging, considering that Vertex's current top-selling CF drug Trikafta/Kaftrio raked in revenue of $10.2 billion last year. Adding to the excitement, the FDA approved Vertex's acute ...
That's encouraging, considering that Vertex's current top-selling CF drug Trikafta/Kaftrio raked in revenue of $10.2 billion last year. Adding to the excitement, the FDA approved Vertex's acute pain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback